Lenalidomide Arrow

Lenalidomide, the active ingredient in Lenalidomide Arrow, is an immunomodulatory imide drug (IMiD) presented as an oral tablet for oral use. It is indicated for the treatment of multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma in adult patients.

GNH USA supplies Lenalidomide Arrow as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, adhering to EU quality standards and ensuring batch traceability for each shipment.

Lenalidomide is an immunomodulatory agent used in hematologic malignancies and related disorders. - Multiple Myeloma: improves progression‑free survival and overall response rates in adult patients. - Myelodysplastic Syndromes with del(5q): reduces transfusion dependence and induces cytogenetic remission. - Mantle Cell Lymphoma: contributes to disease control when combined with other therapies in adult patients.

Lenalidomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may require fluid replacement. - Nausea: feeling of sickness often occurring after dosing. - Rash: mild skin eruptions or itching.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Neutropenia: markedly reduced neutrophil count increasing infection risk. - Secondary primary malignancies: emergence of new cancers. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before prescribing Lenalidomide, clinicians should consider several safety precautions. - Pregnancy risk: contraindicated in pregnancy due to teratogenicity; ensure effective contraception. - Thrombosis prophylaxis: assess need for anticoagulation in patients with additional risk factors. - Renal function: adjust monitoring in patients with impaired kidney function. - Hematologic monitoring: perform regular complete blood counts to detect cytopenias. - Drug interactions: review concomitant medications for potential interactions. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Lenalidomide can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may reduce lenalidomide exposure. - Anticoagulants (e.g., warfarin): increased risk of bleeding when combined with lenalidomide‑induced thrombocytopenia. - Immunosuppressants (e.g., cyclosporine): may enhance hematologic toxicity.

Moderate Interactions (Monitor Closely): - P-glycoprotein inhibitors (e.g., verapamil): may increase plasma levels modestly. - Vaccines: live attenuated vaccines should be avoided during treatment. - Hormonal contraceptives: effectiveness may be reduced; consider additional barrier methods.